Moderna

YTD

ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.

CEO

Stéphane Bancel

CEOStéphane Bancel

Employees

5,800

Employees5,800

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2010

Founded2010

Employees

5,800

Employees5,800

MRNA Key Statistics

Market cap

11.80B

Market cap11.80B

Price-Earnings ratio

-3.50

Price-Earnings ratio-3.50

Dividend yield

—

Dividend yield—

Average volume

10.17M

Average volume10.17M

High today

$30.94

High today$30.94

Low today

$30.20

Low today$30.20

Open price

$30.55

Open price$30.55

Volume

6.97M

Volume6.97M

52 Week high

$129.39

52 Week high$129.39

52 Week low

$23.15

52 Week low$23.15

MRNA News

Simply Wall St 1d

Moderna (NasdaqGS:MRNA) Joins Russell Midcap Indices In Late June 2025

In late June 2025, underwent significant index changes, adding to the Russell Midcap indices while exiting the Russell Top 200 indices. This reclassification mi...

TipRanks 2d

Mixed options sentiment in Moderna with shares up 0.58%

Mixed options sentiment in Moderna (MRNA), with shares up 18c, or 0.58%, near $30.45. Options volume relatively light with 33k contracts traded and calls leadin...

Seeking Alpha 5d

Moderna reports effective results from influenza vaccine trial

Moderna (NASDAQ:MRNA), on Monday, reported positive results from a late-stage study comparing its influenza vaccine candidate, mRNA-1010, to a standard vaccine...

Analyst ratings

64%

of 28 ratings

Buy

21.4%

Hold

64.3%

Sell

14.3%

More MRNA News

Sherwood News 5d

Moderna rises after positive flu vaccine trial results, paving way for combo shot

Moderna rises after positive flu vaccine trial results, paving way for combo shot Modernarose more than 5% in premarket trading after announcing positive resul...

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.